<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1509211052
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Kanvasiv
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CASPOFUNGIN ACETATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        70
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        663.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="HIKMA ITALIA SPA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            HIKMA ITALIA SPA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J02AX04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Kanvasiv is</strong></p><p>Kanvasiv contains a medicine called caspofungin. This belongs to a group of medicines called anti-fungals.</p><p>&nbsp;</p><p><strong>What Kanvasiv is used for</strong></p><p>Kanvasiv is used to treat the following infections in children, adolescents and adults:</p><p>&bull;&nbsp;Serious fungal infections in your tissues or organs (called &lsquo;invasive candidiasis&rsquo;). This infection is caused by fungal (yeast) cells called Candida.</p><p>People who might get this type of infection include those who have just had an operation or those whose immune systems are weak. Fever and chills that do not respond to an antibiotic are the most common signs of this type of infection.</p><p>&bull;&nbsp;Fungal infections in your nose, nasal sinuses or lungs (called &lsquo;invasive aspergillosis&rsquo;) if other anti-fungal treatments have not worked or have caused side effects. This infection is caused by a mould called Aspergillus.</p><p>People who might get this type of infection include those having chemotherapy, those who have had a transplant and those whose immune systems are weak.</p><p>&bull;&nbsp;Suspected fungal infections if you have a fever and a low white cell count that have not improved on treatment with an antibiotic. People who are at risk of getting a fungal infection include those who have just had an operation or those whose immune systems are weak.</p><p>&nbsp;</p><p><strong>How Kanvasiv works</strong></p><p>Kanvasiv makes fungal cells fragile and stops the fungus from growing properly. This stops the infection from spreading and gives the body&rsquo;s natural defences a chance to completely get rid of the infection.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp; If you are allergic to caspofungin or any of the other ingredients of this medicine (listed in section 6).</p><p>If you are not sure, talk to your doctor, nurse or pharmacist before you are given your medicine.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, nurse or pharmacist before you are given Kanvasiv if:</p><p>&bull;&nbsp;&nbsp;&nbsp; You are allergic to any other medicines.</p><p>&bull;&nbsp;&nbsp;&nbsp; You have ever had liver problems - you might need a different dose of this medicine.</p><p>&bull;&nbsp;&nbsp;&nbsp; You are already taking cyclosporin (used to help prevent organ transplant rejection or to suppress your immune system) - as your doctor may need to run extra blood tests during your treatment.</p><p>&bull;&nbsp;&nbsp;&nbsp; If you have ever had any other medical problem.</p><p>If any of the above applies to you (or you are not sure), talk to your doctor, nurse or pharmacist before you are given Kanvasiv.</p><p>Caspofungin may also cause Serious Cutaneous Adverse Reactions such as Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN).</p><p>&nbsp;</p><p><strong>Ot</strong><strong>her medicines and Kanvasiv</strong></p><p>Please tell your doctor, nurse or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription, including herbal medicines.</p><p>This is because Kanvasiv can affect the way some other medicines work. Also, some other medicines can affect the way Kanvasiv works.</p><p>Tell your doctor, nurse or pharmacist if you are taking any of the following medicines:</p><p>&bull;&nbsp;&nbsp;&nbsp; Cyclosporin or tacrolimus (used to help prevent organ transplant rejection or to suppress your immune system) as your doctor may need to run extra blood tests during your treatment</p><p>&bull;&nbsp;&nbsp;&nbsp; Some HIV medicines such as efavirenz or nevirapine</p><p>&bull;&nbsp;&nbsp;&nbsp; Phenytoin or carbamazepine (used for the treatment of seizures)</p><p>&bull;&nbsp;&nbsp;&nbsp; Dexamethasone (a steroid)</p><p>&bull;&nbsp;&nbsp;&nbsp; Rifampicin (an antibiotic)</p><p>If any of the above apply to you (or you are not sure), talk to your doctor, nurse or pharmacist before you are given Kanvasiv.</p><p>&nbsp;</p><p><strong>P</strong><strong>r</strong><strong>egnancy and breast-feeding</strong></p><p>Ask your doctor for advice before taking any medicine, if you are pregnant or breast-feeding or think you are pregnant.</p><p>&bull;&nbsp;&nbsp;&nbsp; Caspofungin has not been studied in pregnant women. It should be used in pregnancy only if the potential benefit justifies the potential risk to the unborn baby.</p><p>&bull;&nbsp;&nbsp;&nbsp; Women given Kanvasiv should not breast-feed.</p><p>&nbsp;</p><p><strong>D</strong><strong>riving and using machines</strong></p><p>There is no information to suggest that caspofungin affects your ability to drive or operate machinery.</p><p>&nbsp;</p><p><strong>Kanvasiv</strong><strong> </strong><strong>contains sucrose and sodium </strong></p><p>Kanvasiv contains sucrose. Each vial of 50 mg and 70 mg contains 35.70 mg or 50 mg sucrose; respectively. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p>Kanvasiv contains sodium. This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Kanvasiv will always be prepared and given to you by a healthcare professional.</p><p>You will be given Kanvasiv:</p><p>&bull;&nbsp;&nbsp;&nbsp; Once each day</p><p>&bull;&nbsp;&nbsp;&nbsp; By slow injection into a vein (intravenous infusion)</p><p>&bull;&nbsp;&nbsp;&nbsp; Over about 1 hour.</p><p>Your doctor will determine the duration of your treatment and how much Kanvasiv you will be given each day. Your doctor will monitor how well the medicine works for you. If you weigh more than 80 kg, you may need a different dose.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>The dose for children and adolescents may differ from the adult dose.</p><p>&nbsp;</p><p><strong>If you have been given more Kanvasiv than you should</strong></p><p>Your doctor will decide how much Kanvasiv you need and for how long each day. If you are worried that you may have been given too much Kanvasiv, tell your doctor or nurse straight away.</p><p>If you have any further questions on the use of this medicine, ask your doctor, nurse or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong><em>Tell your doctor or nurse straight away if you notice any of the following side effects &ndash; you may need urgent medical treatment:</em></strong></p><p>&bull;&nbsp;&nbsp;&nbsp; Rash, itching, feeling warm, swelling of your face, lips or throat or difficulty breathing - you may be having a histamine reaction to the medicine.</p><p>&bull;&nbsp;&nbsp;&nbsp; Difficulty breathing with wheezing or a rash that gets worse - you may be having an allergic reaction to the medicine.</p><p>&bull;&nbsp;&nbsp;&nbsp; Cough, serious breathing difficulties - if you are an adult and have invasive aspergillosis you may be experiencing a serious respiratory problem that could result in respiratory failure.</p><p>&bull;&nbsp;&nbsp;&nbsp; Rash, skin peeling, mucous membrane sores, hives, large areas of peeling skin.</p><p>As with any prescription medicine, some side effects may be serious. Ask your doctor for more information.</p><p>&nbsp;</p><p><strong><em>Other side effects in adults include</em></strong></p><p><strong>Common</strong>: may affect up to 1 in 10 people:</p><p>&bull;&nbsp;&nbsp;&nbsp; Decreased haemoglobin (decreased oxygen carrying substance in the blood), decreased white blood cells</p><p>&bull;&nbsp;&nbsp;&nbsp; Decreased blood albumin (a type of protein) in your blood, decreased potassium or low potassium levels in the blood</p><p>&bull;&nbsp;&nbsp;&nbsp; Headache</p><p>&bull;&nbsp;&nbsp;&nbsp; Inflammation of the vein</p><p>&bull;&nbsp;&nbsp;&nbsp; Shortness of breath</p><p>&bull;&nbsp;&nbsp;&nbsp; Diarrhoea, nausea or vomiting</p><p>&bull;&nbsp;&nbsp;&nbsp; Changes in some laboratory blood tests (including increased values of some liver tests)</p><p>&bull;&nbsp;&nbsp;&nbsp; Itching, rash, skin redness or sweating more than usual</p><p>&bull;&nbsp;&nbsp;&nbsp; Joint pain</p><p>&bull;&nbsp;&nbsp;&nbsp; Chills, fever</p><p>&bull;&nbsp;&nbsp;&nbsp; Itching at the injection site.</p><p><strong>&nbsp;</strong></p><p><strong>Uncommon</strong>: may affect up to 1 in 100 people:</p><p>&bull;&nbsp;&nbsp;&nbsp; Changes in some laboratory blood tests (including disease of blood clotting, platelets, red blood cells and white blood cells)</p><p>&bull;&nbsp;&nbsp;&nbsp; Loss of appetite, increase in amount of body fluid, imbalance of salt in the body, high sugar level in the blood, low calcium level in the blood, increase calcium level in the blood, low magnesium level in the blood, increase in acid level in the blood</p><p>&bull;&nbsp;&nbsp;&nbsp; Disorientation, feeling nervous, being unable to sleep</p><p>&bull;&nbsp;&nbsp;&nbsp; Feeling dizzy, decreased feeling or sensitivity (especially in the skin), shaking, feeling sleepy, change in the way things taste, tingling or numbness</p><p>&bull;&nbsp;&nbsp;&nbsp; Blurred vision, increase in tears, swollen eyelid, yellowing of the whites of the eyes</p><p>&bull;&nbsp;&nbsp;&nbsp; Sensation of fast or irregular heartbeats, rapid heartbeat, irregular heartbeat, abnormal heart rhythm, heart failure</p><p>&bull;&nbsp;&nbsp;&nbsp; Flushing, hot flush, high blood pressure, low blood pressure, redness along a vein which is extremely tender when touched</p><p>&bull;&nbsp;&nbsp;&nbsp; Tightening of the bands of muscle around the airways resulting in wheezing or coughing, fast breathing rate, shortness of breath that wakes you up, shortage of oxygen in the blood, abnormal breath sounds, crackling sounds in the lungs, wheezing, nasal congestion, cough, throat pain</p><p>&bull;&nbsp;&nbsp;&nbsp; Belly pain, upper belly pain, bloating, constipation, difficulty swallowing, dry mouth, indigestion, passing gas, stomach discomfort, swelling due to build-up of fluid around the belly</p><p>&bull;&nbsp;Decreased flow of bile, enlarged liver, yellowing of the skin and/or whites of the eyes, liver injury caused by a drug or chemical, liver disorder</p><p>&bull;&nbsp;Abnormal skin tissue, generalised itching, hives, rash of varying appearance, abnormal skin, red often itchy spots on your arms and legs and sometimes on the face and the rest of the body</p><p>&bull;&nbsp;&nbsp;Back pain, pain in an arm or leg, bone pain, muscle pain, muscle weakness</p><p>&bull;&nbsp;Loss of kidney function, sudden loss of kidney function</p><p>&bull;&nbsp;Catheter site pain, injection site complaints (redness, hard lump, pain, swelling, irritation, rash, hives, leaking of fluid from the catheter into the tissue), inflammation of vein at injection site</p><p>&bull;&nbsp;&nbsp;Increased blood pressure and alterations in some laboratory blood tests (including kidney electrolyte and clotting tests), increased levels of the medicines you are taking that weaken the immune system</p><p>&bull;&nbsp;Chest discomfort, chest pain, feeling of body temperature change, generally feeling unwell, general pain, swelling of the face, swelling of the ankles, hands or feet, swelling, tenderness, feeling tired.</p><p>&nbsp;</p><p><strong><em>Side effects in children and adolescents</em></strong></p><p><strong>Very common: </strong>may affect more than 1 in 10 people:</p><p>&bull;&nbsp;Fever</p><p>&nbsp;</p><p><strong>Common: </strong>may affect up to 1 in 10 people:</p><p>&bull;&nbsp;Headache</p><p>&bull;&nbsp;Fast heart beat</p><p>&bull;&nbsp;Flushing, low blood pressure</p><p>&bull;&nbsp;Changes in some laboratory blood tests (increased values of some liver tests)</p><p>&bull;&nbsp;Itching, rash</p><p>&bull;&nbsp;Catheter site pain</p><p>&bull;&nbsp;Chills</p><p>&bull; Changes in some laboratory blood tests.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Unopened vials: Store in a refrigerator (2-8&deg;C).</p><p>Store in the original package in order to protect from light.</p><p>Once Kanvasiv has been prepared, it should be used straight away. This is because it does not contain any ingredients to stop the growth of bacteria. Only a trained healthcare professional who has read the complete directions should prepare the medicine (please see below &ldquo;Instructions of how to reconstitute and dilute Kanvasiv&rdquo;).</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is caspofungin acetate.</p><p>Each vial of Kanvasiv 50 mg Powder for Concentrate for Solution for Infusion contains 55.52 mg caspofungin acetate equivalent to 50 mg caspofungin.</p><p>Each vial of Kanvasiv 70 mg Powder for Concentrate for Solution for Infusion contains 77.69 mg caspofungin acetate equivalent to 70 mg caspofungin.</p><p>The other ingredients are sucrose, mannitol, glacial acetic acid and sodium hydroxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Kanvasiv 50 mg and 70 mg Powder for Concentrate for Solution for Infusion is a white to off white lyophilized powder in 10 ml clear type I glass vials, sealed with bromo-butyl rubber stoppers and aluminum band with plastic flip-off caps.

Pack size: 1 Vial.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. BOX 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Hikma Italia S.P.A.<br />Viale Certosa, 10<br />27100 Pavia, Italy<br />Tel: + (39-0382) 1751844, + (39-0382) 1751801<br />Fax: + (39-0382) 422745</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 06/2021; version number SA1.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو كانڤيزڤ</strong></p><p dir="RTL">يحتوي كانڤيزڤ على دواء يسمى كاسبوفونجين. ينتمي هذا الدواء إلى مجموعة من الأدوية تسمى مضادات الفطريات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما هي دواعي استخدام كانڤيزڤ</strong></p><p dir="RTL">يستخدم كانڤيزڤ في علاج الأنواع التالية من العدوى لدى الأطفال والمراهقين والبالغين:</p><p dir="RTL">&bull;&nbsp;حالات العدوى الفطرية الخطيرة في الأنسجة أو الأعضاء (تسمى عدوى &quot;المبيضات الاجتياحية&quot;) تحدث هذه العدوى بسبب خلايا (الخميرة) الفطرية المعروفة باسم كانديدا.</p><p dir="RTL">يشمل الأشخاص الذين يُحتمل إصابتهم بهذا النوع من العدوى الأفراد الذين أجروا عملية أو الذين لديهم ضعف في جهاز المناعة. تعتبر الحمّى والقشعريرة التي لا تستجيب لأي مضاد حيوي أكثر العلامات شيوعاً لهذا النوع من العدوى.</p><p dir="RTL">&bull;&nbsp;حالات العدوى الفطرية في الأنف أو الجيوب الأنفية أو الرئتين المعروفة باسم داء &quot;الرشاشيات المتغلغل&quot;) إذا لم تُجدِ العلاجات المضادة للفطريات الأخرى نفعاً أو تسببت في حدوث آثار جانبية. تحدث هذه العدوى بسبب عفن يُسمى الرشاشيات.</p><p dir="RTL">يشمل الأشخاص الذين يُحتمل إصابتهم بهذا النوع من العدوى الأفراد الذين يخضعون للعلاج الكيماوي والذين خضعوا لعملية زراعة والذين لديهم ضعف في جهاز المناعة.</p><p dir="RTL">&bull;&nbsp;حالات العدوى الفطرية المشتبه فيها في حال كنت تعاني من حمّى وانخفاض في عدد الخلايا البيضاء التي لا تتحسن بتلقي علاج بأي مضاد حيوي. يشمل الأشخاص المعرضون لخطر الإصابة بعدوى فطرية الأفراد الذين أجروا عملية أو الذين لديهم ضعف في جهاز المناعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة عمل كانڤيزڤ</strong></p><p dir="RTL">يعمل كانڤيزڤ على إضعاف الخلايا الفطرية وإيقاف نمو الفطريات بشكل سليم. وهذا يوقف انتشار العدوى ويمنح الدفاعات الطبيعية بالجسم فرصة للتخلص من العدوى تماماً.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا ينبغي إعطائك</strong><strong> </strong><strong>كانڤيزڤ</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية لكاسبوفونجين أو لأي من المواد الأخرى المستخدمة في تركيبة هذا الدواء (المذكورة في القسم 6).</p><p dir="RTL">إذا لم تكن متأكداً، فتحدث مع طبيبك، الممرض، أو الصيدلي قبل إعطائك الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات والتحذيرات</strong></p><p dir="RTL">تحدث مع طبيبك، الممرض، أو الصيدلي قبل إعطائك كانڤيزڤ إذا:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; كنت تعاني من حساسية لأي أدوية أخرى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; كنت تعاني من مشاكل في الكبد في السابق، فربما تحتاج إلى جرعة مختلفة من هذا الدواء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; كنت تأخذ بالفعل سيكلوسبورين (الذي يستخدم في الوقاية من رفض زرع الأعضاء أو لتثبيط الجهاز المناعي)، نظراً إلى أن طبيبك قد يحتاج إلى إجراء المزيد من فحوصات الدم في أثناء العلاج.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; عانيت مسبقاً من أي مشاكل طبية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان ينطبق عليك أي مما سبق (أو لم تكن متأكداً)، فتحدث مع طبيبك، الممرض، أو الصيدلي قبل إعطائك كانڤيزڤ.</p><p dir="RTL">قد يسبب كاسبوفونجين أيضاً تفاعلات جلدية ضارة خطيرة مثل متلازمة ستيفنز-جونسون وتقشر الأنسجة المتموتة البشروية التسممي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وكانڤيزڤ</strong></p><p dir="RTL">يرجى إخبار طبيبك، الممرض، أو الصيدلي إذا كنت تأخذ، أخذت مؤخراً، أو قد تأخذ أية أدوية أخرى. ويشمل ذلك الأدوية التي حصلت عليها بدون وصفة طبية، بما في ذلك الأدوية العشبية.</p><p dir="RTL">ذلك لأن كانڤيزڤ قد يؤثر على طريقة عمل بعض الأدوية الأخرى. وبعض الأدوية الأخرى قد تؤثر أيضاً على طريقة عمل كانڤيزڤ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أبلغ طبيبك، الممرض، أو الصيدلي إذا كنت تتناول أيَّاً من الأدوية التالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; سيكلوسبورين أو تاكروليمس (المستخدمين في الوقاية من رفض زرع الأعضاء أو لتثبيط الجهاز المناعي)، نظراً إلى أن طبيبك قد يحتاج إلى إجراء المزيد من فحوصات الدم في أثناء العلاج</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; بعض أدوية فيروس العوز المناعي البشري مثل إيفافيرينز أو نيفيرابين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; فينيتوين أو كاربامازيبين (المستخدمان في علاج نوبات الصرع)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; ديكساميثازون (ستيرويد)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; ريفامبيسين (مضاد حيوي)</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان ينطبق عليك أي مما سبق (أو لم تكن متأكداً)، فتحدث مع طبيبك، الممرض، أو الصيدلي قبل إعطائك كانڤيزڤ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong>&nbsp;</p><p dir="RTL">يرجى استشارة طبيبكِ قبل أخذ أي دواء إذا كنتِ حاملاً أو مرضع، أو تعتقدين بأنك حاملاً.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; لم يخضع كاسبوفونجين للدراسة لدى النساء الحوامل. لا ينبغي استخدامه أثناء الحمل إلا إذا كانت الفائدة المحتملة تبرر الخطر المحتمل على الجنين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; تُحظر الرضاعة على النساء اللاتي يتم إعطاؤهن كانڤيزڤ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">لا تتوفر معلومات تشير إلى أن كاسبوفونجين يؤثر على قدرتك على القيادة أو تشغيل الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي</strong><strong> </strong><strong>كانڤيزڤ على السكروز والصوديوم</strong> <strong>&nbsp;</strong></p><p dir="RTL">يحتوي كانڤيزڤ على السكروز. تحتوي كل زجاجة من 50 ملغم و70 ملغم على 35.70 ملغم أو 50 ملغم سكروز؛ على التوالي. إذا أخبرك طبيبك أنك تعاني من عدم تحمل تجاه بعض السكريات، فاتصل عليه قبل تناول هذا المستحضر الدوائي.</p><p>يحتوي كانڤيزڤ على الصوديوم. يحتوي هذا الدواء على أقل من 1 ملمول صوديوم (23 ملغم) لكل زجاجة، بمعنى أنه &rsquo;خالٍ من الصوديوم&lsquo; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيقوم أحد متخصصي الرعاية بإعداد كانڤيزڤ دائماً وإعطائه لك.</p><p dir="RTL">سيتم إعطاؤك كانڤيزڤ:</p><p dir="RTL">&bull;&nbsp;&nbsp;مرة واحدة يومياً</p><p dir="RTL">&bull;&nbsp;&nbsp;بالحقن البطيء في أحد الأوردة (التسريب الوريدي)</p><p dir="RTL">&bull;&nbsp;&nbsp;على مدار أكثر من ساعة تقريباً.</p><p dir="RTL">سيحدد طبيبك فترة علاجك والجرعة التي سيتم إعطاؤك إياها يومياً. سيراقب طبيبك مدى فاعلية الدواء عليك. إذا كان وزنك أكثر من 80 كغم، فقد تحتاج إلى جرعة مختلفة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">قد تختلف جرعة الأطفال والمراهقين عن جرعة البالغين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;<strong>إذا تم إعطاؤك</strong><strong> </strong><strong>كانڤيزڤ</strong> <strong>أكثر من اللازم</strong></p><p dir="RTL">سيقرر طبيبك الجرعة المطلوبة من كانڤيزڤ ومدة إعطائها يومياً. إذا ساورك القلق بأنه قد تم إعطاؤك جرعة زائدة من كانڤيزڤ، فأبلغ طبيبك أو الممرض على الفور.</p><p>إذا كان لديك أية أسئلة إضافية حول استخدام هذا الدواء، يرجى استشارة الطبيب أو الممرض أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبيةً، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL"><strong><em>أخبر طبيبك أو الممرض على الفور، إذا لاحظت أيَّاً من الآثار الجانبية التالية لأنك قد تحتاج إلى علاج طبي عاجل</em></strong><strong><em>:</em></strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; طفح جلدي أو حكة أو شعور بالسخونة أو تورم بوجهك أو شفتيك أو حلقك أو صعوبة في التنفس - فربما تكون مصاباً برد الفعل الهستاميني تجاه الدواء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; صعوبة في التنفس مصحوب بصفير أو طفح جلدي يتفاقم - فربما تعاني من رد فعل تحسسي تجاه الدواء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; سعال أو صعوبات شديدة في التنفس - إذا كنت بالغاً وتعاني من داء الرشاشيات المتغلغل فقد تعاني من مشكلة خطيرة في التنفس يمكن أن تؤدي إلى فشل تنفسي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; طفح جلدي أو تقشر الجلد أو تقرحات الأغشية المخاطية أو شرى أو مواضع كبيرة من تقشر الجلد.</p><p dir="RTL">كما هو الحال مع أي دواء يُصرف بوصفة طبية، يوجد بعض الآثار الجانبية الخطيرة. اطلب من طبيبك الحصول على مزيد من المعلومات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>تشمل الآثار الجانبية الأخرى لدى البالغين</em></strong></p><p dir="RTL"><strong>شائعة</strong>: قد تؤثر على ما يصل إلى شخص واحد من بين 10 أشخاص:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; انخفاض الهيموغلوبين (انخفاض المادة الحاملة للأكسجين في الدم)، أو انخفاض خلايا الدم البيضاء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; انخفاض الألبومين (نوع من البروتين) في الدم، أو نقص البوتاسيوم أو انخفاض مستوى البوتاسيوم في الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; التهاب الوريد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; ضيق التنفس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; إسهال أو غثيان أو قيء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; تغيرات في نتائج بعض فحوصات الدم المخبرية (تشمل زيادة في قيم بعض نتائج اختبارات الكبد)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; حكة أو طفح جلدي أو احمرار الجلد أو تعرّق أكثر من المعتاد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; ألم في المفاصل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; قشعريرة أو حمّى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; حكة عند موضع الحقن.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>غير شائعة</strong>: قد تؤثر على ما يصل إلى شخص واحد من بين 100 شخص:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; تغيرات في بعض فحوصات الدم المخبرية (تشمل مرض تجلط الدم والصفائح الدموية وخلايا الدم الحمراء وخلايا الدم البيضاء)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; فقدان الشهية أو زيادة في كمية سوائل الجسم أو اختلال توازن الأملاح في الجسم أو ارتفاع مستوى السكر في الدم أو انخفاض مستوى الكالسيوم في الدم أو زيادة مستوى الكالسيوم في الدم أو انخفاض مستوى المغنيسيوم في الدم أو زيادة مستوى الأحماض في الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; توهان أو شعور بالتوتر أو عدم القدرة على النوم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; شعور بدوخة أو انخفاض الشعور أو الحساسية (خصوصاً في الجلد) أو ارتعاش أو شعور بالنعاس أو تغير في طريقة تذوق الأشياء أو وخز أو تنميل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; تشوش الرؤية أو زيادة الدموع أو تورم جفن العين أو اصفرار بياض العينين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; إحساس بنبضات قلب سريعة أو غير منتظمة أو سرعة نبض القلب أو عدم انتظام نبضات القلب أو اضطراب نظم القلب أو فشل القلب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; احمرار الوجه أو تورد أو ارتفاع ضغط الدم أو انخفاض ضغط الدم أو احمرار على طول الوريد ويكون موجعاً جداً عند لمسه</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; تصلب مجموعة العضلات حول المسالك الهوائية مما يؤدي إلى صفير أو سعال، أو سرعة معدل التنفس، أو ضيق تنفس يوقظك من النوم، أو نقص الأكسجين في الدم، أو أصوات تنفس غير طبيعية، أو أصوات طقطقة في الرئتين، أو صفير، أو انسداد الأنف أو سعال أو ألم بالحلق</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; ألم في البطن أو ألم في الجزء العلوي من البطن أو انتفاخ أو إمساك أو صعوبة في البلع أو جفاف الفم أو عسر الهضم أو خروج غازات أو مغص بالمعدة أو تورم بسبب تراكم السوائل حول البطن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; انخفاض في تدفق العصارة الصفراوية، أو تضخم الكبد، أو اصفرار الجلد وبياض العينين أو أحدهما، أو إصابة الكبد بسبب دواء أو مادة كيميائية، أو اضطراب الكبد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; نسيج جلد غير طبيعي أو حكة عامة أو شرى أو طفح جلدي يتفاوت في معدل ظهوره أو جلد غير طبيعي أو بقع حمراء غالباً تسبب الحكة في ذراعيك وساقيك وأحياناً على الوجه وبقية الجسم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; ألم بالظهر أو ألم في أحد الذراعين أو الرجلين وألم في العظم وألم بالعضلات أو ضعف بالعضلات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; فقدان وظائف الكلى أو فقدان مفاجئ لوظيفة الكلى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; ألم عند موضع القثطار أو مضاعفات عند موضع الحقن (احمرار أو كتلة صلبة أو ألم أو تورم أو تهيج أو طفح جلدي أو شرى أو تسرب السائل من القثطار إلى الأنسجة) أو التهاب الوريد عند موضع الحقن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; زيادة ضغط الدم وتغييرات في بعض فحوصات الدم المخبرية (تشمل اختبارات التخثر والكهارل بالكلى) أو زيادة مستويات الأدوية التي تأخذها والتي تضعف جهاز المناعة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; شعور بعدم الراحة في الصدر أو ألم في الصدر أو شعور بتغير في درجة حرارة الجسم أو شعور عام بالتوعك أو ألم عام أو تورم في الوجه أو تورم في الكاحل أو اليدين أو القدمين أو تورم أو عدم شعور بالراحة أو شعور بالتعب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>آثار جانبية أخرى قد تحدث لدى الأطفال والمراهقين</em></strong></p><p dir="RTL"><strong>شائعة جداً</strong><strong>: </strong>قد تؤثر على أكثر من شخص واحد من بين 10 أشخاص:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; حمّى</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong><strong>: </strong>قد تؤثر على ما يصل إلى شخص واحد من بين 10 أشخاص:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; سرعة نبضات القلب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; تورّد، انخفاض ضغط الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; تغيرات في نتائج بعض الفحوصات المخبرية (زيادة في قيم بعض نتائج اختبارات الكبد)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; حكة، أو طفح</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; ألم عند موضع القثطار</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; قشعريرة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; تغييرات في نتائج بعض فحوصات الدم المخبرية</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">الزجاجات قبل الفتح: يحفظ داخل الثلاجة (2-8&deg; مئوية).</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الضوء.</p><p dir="RTL">يجب استخدام كانڤيزڤ على الفور بمجرد تحضيره. وذلك لأنه لا يحتوي على أي مكونات من شأنها إيقاف نمو البكتيريا. يجب فقط على أخصائي الرعاية الصحية المدرب الذي قرأ التعليمات الكاملة تحضير الدواء (يرجى الرجوع إلى &quot;تعليمات حول كيفية تحضير كانڤيزڤ وتخفيفه&quot; أدناه).</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد عبارة &quot;EXP&quot;. يشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت علامات تلف واضحة عليه.</p><p>لا تتخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. اتبع هذه الإجراءات للحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي أسيتات الكاسبوفونجين.</p><p dir="RTL">تحتوي كل زجاحة من كانڤيزڤ 50 ملغم مسحوق لتشكيل المركز ثم التخفيف قبل التسريب على 55.52 ملغم أسيتات الكاسبوفونجين تكافئ 50 ملغم كاسبوفونجين.</p><p dir="RTL">تحتوي كل زجاحة من كانڤيزڤ 70 ملغم مسحوق لتشكيل المركز ثم التخفيف قبل التسريب على 77.69&nbsp; ملغم أسيتات الكاسبوفونجين تكافئ 70 ملغم كاسبوفونجين.</p><p>المواد الأخرى المستخدمة في التركيبة التصنيعية هي سكروز، مانیتول، حمض الأسیتیك الثلجي وھیدروكسید الصودیوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify">كانڤيزڤ 50 ملغم و70 ملغم مسحوق لتشكيل المركز ثم التخفيف قبل التسريب هو مسحوق مجفد لونه أبيض مائل إلى الأصفر معبأ في زجاجة بحجم 10 مللتر شفافة من النوع 1 محكمة الإغلاق بسدادات مطاطية من البروموبوتيل وشريط من الألومنيوم ومع أغطية بلاستيكية قابلة للفتح لأعلى.</p><p dir="RTL" style="text-align:justify">حجم العبوة: زجاجة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان مالك رخصة التسويق</strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية</p><p dir="RTL">هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">شركة الحكمة إيطاليا<br />فيالي سيرتوزا، 10<br />27100 بافيا، إيطاليا<br />هاتف: 1751844 (0382-39) +، 1751801 (0382-39) +<br />فاكس: 422745 (0382-39) +</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            
تمت مراجعة هذه النشرة بتاريخ 06/2021؛ رقم النسخة SA1.0.

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Kanvasiv 70 mg Powder for Concentrate for Solution for Infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains 77.69 mg caspofungin acetate equivalent to 70 mg caspofungin.

Excipients with known effect: Sucrose and sodium. 

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for concentrate for solution for infusion.

White to off white lyophilized powder.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">&bull;&nbsp;&nbsp;&nbsp; Treatment of invasive candidiasis in adult or paediatric patients.</p><p style="text-align:justify">&bull;&nbsp;&nbsp;&nbsp;Treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and/or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.</p><p style="text-align:justify">Empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic adult or paediatric patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Caspofungin should be initiated by a physician experienced in the management of invasive fungal infections.</p><p>&nbsp;</p><p><u>Posology</u></p><p><em>Adult patients</em></p><p>A single 70 mg loading dose should be administered on Day-1, followed by 50 mg daily thereafter. In patients weighing more than 80 kg, after the initial 70 mg loading dose, caspofungin 70 mg daily is recommended (see section 5.2). No dosage adjustment is necessary based on gender or race (see section 5.2).</p><p>&nbsp;</p><p><em>Paediatric patients (12 months to 17 years)</em></p><p>In paediatric patients (12 months to 17 years of age), dosing should be based on the patient&#39;s body surface area (see Instructions for Use in Paediatric Patients, Mosteller<sup>1</sup>&nbsp;Formula). For all indications, a single 70-mg/m<sup>2</sup>&nbsp;loading dose (not to exceed an actual dose of 70 mg) should be administered on Day 1, followed by 50 mg/m<sup>2</sup>&nbsp;daily thereafter (not to exceed an actual dose of 70 mg daily). If the 50-mg/m<sup>2</sup>&nbsp;daily dose is well tolerated but does not provide an adequate clinical response, the daily dose can be increased to 70 mg/m<sup>2</sup>&nbsp;daily (not to exceed an actual daily dose of 70 mg).</p><p>The safety and efficacy of caspofungin have not been sufficiently studied in clinical trials involving neonates and infants below 12 months of age. Caution is advised when treating this age group. Limited data suggest that caspofungin at 25 mg/m<sup>2</sup>&nbsp;daily in neonates and infants (less than 3 months of age) and 50 mg/m<sup>2</sup>&nbsp;daily in young children (3 to 11 months of age) can be considered (see section 5.2).</p><p>&nbsp;</p><p><u>Duration of treatment</u></p><p>Duration of empirical therapy should be based on the patient&#39;s clinical response. Therapy should be continued until up to 72 hours after resolution of neutropaenia (ANC&ge; 500). Patients found to have a fungal infection should be treated for a minimum of 14 days and treatment should continue for at least 7 days after both neutropaenia and clinical symptoms are resolved.</p><p>Duration of treatment of invasive candidiasis should be based upon the patient&#39;s clinical and microbiological response. After signs and symptoms of invasive candidiasis have improved and cultures have become negative, a switch to oral antifungal therapy may be considered. In general, antifungal therapy should continue for at least 14 days after the last positive culture.</p><p>Duration of treatment of invasive aspergillosis is determined on a case by case basis and should be based upon the severity of the patient&#39;s underlying disease, recovery from immunosuppression, and clinical response. In general, treatment should continue for at least 7 days after resolution of symptoms.</p><p>The safety information on treatment durations longer than 4 weeks is limited. However, available data suggest that caspofungin continues to be well tolerated with longer courses of therapy (up to 162 days in adult patients and up to 87 days in paediatric patients).</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>Elderly patients</em></p><p>In elderly patients (65 years of age or more), the area under the curve (AUC) is increased by approximately 30 %. However, no systematic dosage adjustment is required. There is limited treatment experience in patients 65 years of age and older (see section 5.2).</p><p><em>Renal impairment</em></p><p>No dosage adjustment is necessary based on renal impairment (see section 5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>For adult patients with mild hepatic impairment (Child-Pugh score 5 to 6), no dosage adjustment is needed. For adult patients with moderate hepatic impairment (Child-Pugh score 7 to 9), caspofungin 35 mg daily is recommended based upon pharmacokinetic data. An initial 70 mg loading dose should be administered on Day-1. There is no clinical experience in adult patients with severe hepatic impairment (Child-Pugh score greater than 9) and in paediatric patients with any degree of hepatic impairment (see section 4.4).</p><p>&nbsp;</p><p><u>Co-administration with inducers of metabolic enzymes</u></p><p>Limited data suggest that an increase in the daily dose of caspofungin to 70 mg, following the 70 mg loading dose, should be considered when co-administering caspofungin in adult patients with certain inducers of metabolic enzymes (see section 4.5). When caspofungin is co-administered to paediatric patients (12 months to 17 years of age) with these same inducers of metabolic enzymes (see section 4.5), a caspofungin dose of 70-mg/m<sup>2</sup>&nbsp;daily (not to exceed an actual daily dose of 70 mg) should be considered.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>After reconstitution and dilution, the solution should be administered by slow intravenous infusion over approximately 1 hour. For reconstitution directions see section 6.6.</p><p>Both 70 mg and 50 mg vials are available.</p><p>Caspofungin should be given as a single daily infusion.</p><p><sup>1</sup>&nbsp;Mosteller RD: Simplified Calculation of Body Surface Area.&nbsp;<em>N Engl J Med</em>&nbsp;1987 Oct 22;317(17):1098 (letter)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Anaphylaxis has been reported during administration of caspofungin. If this occurs, caspofungin should be discontinued and appropriate treatment administered. Possibly histamine-mediated adverse reactions, including rash, facial swelling, angioedema, pruritus, sensation of warmth, or bronchospasm have been reported and may require discontinuation and/or administration of appropriate treatment.</p><p>Limited data suggest that less common non-<em>Candida</em>&nbsp;yeasts and non-<em>Aspergillus</em>&nbsp;moulds are not covered by caspofungin. The efficacy of caspofungin against these fungal pathogens has not been established.</p><p>Concomitant use of caspofungin with ciclosporin has been evaluated in healthy adult volunteers and in adult patients. Some healthy adult volunteers who received two 3 mg/kg doses of ciclosporin with caspofungin showed transient increases in alanine transaminase (ALT) and aspartate transaminase (AST) of less than or equal to 3-fold the upper limit of normal (ULN) that resolved with discontinuation of the treatment. In a retrospective study of 40 patients treated during marketed use with caspofungin and ciclosporin for 1 to 290 days (median 17.5 days), no serious hepatic adverse reactions were noted. These data suggest that caspofungin can be used in patients receiving ciclosporin when the potential benefit outweighs the potential risk. Close monitoring of liver enzymes should be considered if caspofungin and ciclosporin are used concomitantly.</p><p>In adult patients with mild and moderate hepatic impairment, the AUC is increased about 20% and 75 %, respectively. A reduction of the daily dose to 35 mg is recommended for adults with moderate hepatic impairment. There is no clinical experience in adults with severe hepatic impairment or in paediatric patients with any degree of hepatic impairment. A higher exposure than in moderate hepatic impairment is expected and caspofungin should be used with caution in these patients (see sections 4.2 and 5.2).</p><p>Laboratory abnormalities in liver function tests have been seen in healthy volunteers and adult and paediatric patients treated with caspofungin. In some adult and paediatric patients with serious underlying conditions who were receiving multiple concomitant medications with caspofungin, cases of clinically significant hepatic dysfunction, hepatitis and hepatic failure have been reported; a causal relationship to caspofungin has not been established. Patients who develop abnormal liver function tests during caspofungin therapy should be monitored for evidence of worsening hepatic function and the risk/benefit of continuing caspofungin therapy should be re-evaluated.</p><p>Cases of Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported after post-marketing use of caspofungin. Caution should apply in patients with history of allergic skin reaction (see section 4.8).</p><p>Kanvasiv contains sucrose. Each vial contains 50 mg sucrose. Patients with rare hereditary problems of fructose intolerance or sucrase-isomaltase insufficiency should not take this medicinal product.</p><p>Kanvasiv contains sodium. This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Studies&nbsp;<em>in vitro</em>&nbsp;show that caspofungin is not an inhibitor of any enzyme in the cytochrome P450 (CYP) system. In clinical studies, caspofungin did not induce the CYP3A4 metabolism of other substances. Caspofungin is not a substrate for P-glycoprotein and is a poor substrate for cytochrome P450 enzymes. However, caspofungin has been shown to interact with other medicinal products in pharmacological and clinical studies (see below).</p><p>In two clinical studies performed in healthy adult subjects, ciclosporin A (one 4 mg/kg dose or two 3 mg/kg doses 12 hours apart) increased the AUC of caspofungin by approximately 35 %. These AUC increases are probably due to reduced uptake of caspofungin by the liver. &nbsp;Caspofungin did not increase the plasma levels of ciclosporin. There were transient increases in liver ALT and AST of less than or equal to 3-fold the upper limit of normal (ULN) when caspofungin and ciclosporin were co-administered, that resolved with discontinuation of the medicinal products. In a retrospective study of 40 patients treated during marketed use with caspofungin and ciclosporin for 1 to 290 days (median 17.5 days), no serious hepatic adverse reactions were noted (see section 4.4). Close monitoring of liver enzymes should be considered if the two medicinal products are used concomitantly.</p><p>Caspofungin reduced the trough concentration of tacrolimus by 26 % in healthy adult volunteers. For patients receiving both therapies, standard monitoring of tacrolimus blood concentrations and appropriate tacrolimus dosage adjustments are mandatory.</p><p>Clinical studies in healthy adult volunteers show that the pharmacokinetics of caspofungin are not altered to a clinically relevant extent by itraconazole, amphotericin B, mycophenolate, nelfinavir, or tacrolimus. Caspofungin did not influence the pharmacokinetics of amphotericin B, itraconazole, rifampicin or mycophenolate mofetil. Although safety data are limited it appears that no special precautions are needed when amphotericin B, itraconazole, nelfinavir or mycophenolate mofetil are co-administered with caspofungin.</p><p>Rifampicin caused a 60 % increase in AUC and 170 % increase in trough concentration of caspofungin on the first day of co-administration when both medicinal products were initiated together in healthy adult volunteers. Caspofungin trough levels gradually decreased upon repeated administration. After two weeks&#39; administration rifampicin had limited effect on AUC, but trough levels were 30 % lower than in adult subjects who received caspofungin alone. The mechanism of interaction could possibly be due to an initial inhibition and subsequent induction of transport proteins. A similar effect could be expected for other medicinal products that induce metabolic enzymes. Limited data from population pharmacokinetics studies indicate that concomitant use of caspofungin with the inducers efavirenz, nevirapine, rifampicin, dexamethasone, phenytoin, or carbamazepine may result in a decrease in caspofungin AUC. When co-administering inducers of metabolic enzymes, an increase in the daily dose of caspofungin to 70 mg, following the 70 mg loading dose, should be considered in adult patients (see section 4.2).</p><p>All adult drug-drug interaction studies described above were conducted at a 50 or 70 mg daily caspofungin dose. The interaction of higher doses of caspofungin with other medicinal products has not been formally studied.</p><p>In paediatric patients, results from regression analyses of pharmacokinetic data suggest that co-administration of dexamethasone with caspofungin may result in clinically meaningful reductions in caspofungin trough concentrations. This finding may indicate that paediatric patients will have similar reductions with inducers as seen in adults. When caspofungin is co-administered to paediatric patients (12 months to 17 years of age) with inducers of drug clearance, such as rifampicin, efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, a caspofungin dose of 70-mg/m<sup>2</sup>&nbsp;daily (not to exceed an actual daily dose of 70 mg) should be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no or limited data from the use of caspofungin in pregnant women. Caspofungin should not be used during pregnancy unless clearly necessary. Animal studies have shown developmental toxicity (see section 5.3). Caspofungin has been shown to cross the placental barrier in animal studies.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>It is unknown whether caspofungin is excreted in human milk. Available pharmacodynamic/ toxicological data in animals have shown excretion of caspofungin in milk. Women receiving caspofungin should not breast-feed.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>For caspofungin, there were no effects on fertility in studies conducted in male and female rats (see section 5.3). There are no clinical data for caspofungin to assess its impact on fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypersensitivity reactions (anaphylaxis and possibly histamine-mediated adverse reactions) have been reported (see section 4.4).</p><p>Also reported in patients with invasive aspergillosis were pulmonary oedema, adult respiratory distress syndrome (ARDS), and radiographic infiltrates.</p><p>&nbsp;</p><p><u>Adult patients</u></p><p>In clinical studies, 1,865 adult individuals received single or multiple doses of caspofungin: 564 febrile neutropaenic patients (empirical therapy study), 382 patients with invasive candidiasis, 228 patients with invasive aspergillosis, 297 patients with localised&nbsp;<em>Candida</em>&nbsp;infections, and 394 individuals enrolled in Phase I studies. In the empirical therapy study patients had received chemotherapy for malignancy or had undergone haematopoietic stem-cell transplantation (including 39 allogeneic transplantations). In the studies involving patients with documented&nbsp;<em>Candida</em>&nbsp;infections, the majority of the patients with invasive&nbsp;<em>Candida</em>&nbsp;infections had serious underlying medical conditions (e.g., haematologic or other malignancy, recent major surgery, HIV) requiring multiple concomitant medications. Patients in the non-comparative&nbsp;<em>Aspergillus</em>&nbsp;study often had serious predisposing medical conditions (e.g., bone marrow or peripheral stem cell transplants, haematologic malignancy, solid tumours or organ transplants) requiring multiple concomitant medications.</p><p>Phlebitis was a commonly reported local injection-site adverse reaction in all patient populations. Other local reactions included erythema, pain/tenderness, itching, discharge, and a burning sensation.</p><p>Reported clinical and laboratory abnormalities among all adults treated with caspofungin (total 1,780) were typically mild and rarely led to discontinuation.</p><p><em>Tabulated list of adverse reactions</em></p><p>The following adverse reactions were reported during clinical studies and/or post-marketing use:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common (&ge;1/100 to &lt;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon (&ge;1/1,000 to &lt;1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Not known (cannot be estimated from available data)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>haemoglobin decreased, haematocrit decreased, white blood cell count decreased</p></td><td style="vertical-align:top"><p>anaemia, thrombocytopaenia, coagulopathy, leukopaenia, eosinophil count increased, platelet count decreased, platelet count increased, lymphocyte count decreased, white blood cell count increased, neutrophil count decreased</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>hypokalemia</p></td><td style="vertical-align:top"><p>fluid overload, hypomagnesaemia, anorexia, electrolyte imbalance, hyperglycaemia, hypocalcaemia, metabolic acidosis</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>anxiety, disorientation, insomnia</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>dizziness, dysgeusia, paraesthesia, somnolence, tremor, hypoaesthesia</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>ocular icterus, vision blurred, eyelid oedema, lacrimation increased</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>palpitations, tachycardia, arrhythmia, atrial fibrillation, cardiac failure congestive</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>phlebitis</p></td><td style="vertical-align:top"><p>thrombophlebitis, flushing, hot flush, hypertension, hypotension</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>dyspnoea</p></td><td style="vertical-align:top"><p>nasal congestion, pharyngolaryngeal pain, tachypnoea, bronchospasm, cough, dyspnoea paroxysmal nocturnal, hypoxia, rales, wheezing</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>nausea, diarrhoea, vomiting</p></td><td style="vertical-align:top"><p>abdominal pain, abdominal pain upper, dry mouth, dyspepsia, stomach discomfort, abdominal distension, ascites, constipation, dysphagia, flatulence</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>elevated liver values (alanine aminotransferase, aspartate aminotransferase, blood alkaline phosphatase, bilirubin conjugated, blood bilirubin)</p></td><td style="vertical-align:top"><p>cholestasis, hepatomegaly, hyperbilirubinaemia, jaundice, hepatic function abnormal, hepatotoxicity, liver disorder, gamma-glutamyltransferase increased</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>rash, pruritus, erythema, hyperhidrosis</p></td><td style="vertical-align:top"><p>erythema multiforme, rash macular, rash maculo-papular, rash pruritic, urticaria, dermatitis allergic, pruritus generalised, rash erythematous, rash generalised, rash morbilliform, skin lesion</p></td><td style="vertical-align:top"><p>Toxic epidermal necrolysis and Stevens-Johnson syndrome (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>arthralgia</p></td><td style="vertical-align:top"><p>back pain, pain in extremity, bone pain, muscular weakness, myalgia</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>renal failure, renal failure acute</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>pyrexia, chills, infusion-site pruritus</p></td><td style="vertical-align:top"><p>pain, catheter site pain, fatigue, feeling cold, feeling hot, infusion site erythema, infusion site induration, infusion site pain, infusion site swelling, injection site phlebitis, oedema peripheral, tenderness, chest discomfort, chest pain, face oedema, feeling of body temperature change, induration, infusion site extravasation, infusion site irritation, infusion site phlebitis, infusion site rash, infusion site urticaria, injection site erythema, injection site oedema, injection site pain, injection site swelling, malaise, oedema</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>blood potassium decreased, blood albumin decreased</p></td><td style="vertical-align:top"><p>blood creatinine increased, red blood cells urine positive, protein total decreased, protein urine present, prothrombin time prolonged, prothrombin time shortened, blood sodium decreased, blood sodium increased, blood calcium decreased, blood calcium increased, blood chloride decreased, blood glucose increased, blood magnesium decreased, blood phosphorus decreased, blood phosphorus increased, blood urea increased, activated partial thromboplastin time prolonged, blood bicarbonate decreased, blood chloride increased, blood potassium increased, blood pressure increased, blood uric acid decreased, blood urine present, breath sounds abnormal, carbon dioxide decreased, immunosuppressant drug level increased, international normalised ratio increased, urinary casts, white blood cells urine positive, and pH urine increased.</p></td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>Caspofungin has also been evaluated at 150 mg daily (for up to 51 days) in 100 adult patients (see section 5.1). The study compared caspofungin at 50 mg daily (following a 70-mg loading dose on Day 1) versus 150 mg daily in the treatment of invasive candidiasis. In this group of patients, the safety of caspofungin at this higher dose appeared generally similar to patients receiving the 50-mg daily dose of caspofungin. The proportion of patients with a serious drug-related adverse reaction or a drug-related adverse reaction leading to caspofungin discontinuation was comparable in the 2 treatment groups.</p><p>&nbsp;</p><p><u>Paediatric Patients</u></p><p>Data from 5 clinical studies completed in 171 paediatric patients suggest that the overall incidence of clinical adverse experiences (26.3%; 95% CI -19.9, 33.6) is not worse than reported for adults treated with caspofungin (43.1%; 95% CI -40.0, 46.2). However, paediatric patients probably have a different adverse event profile compared to adult patients. The most common drug-related clinical adverse experiences reported in paediatric patients treated with caspofungin were pyrexia (11.7%), rash (4.7%) and headache (2.9%).</p><p>&nbsp;</p><p><em>Tabulated list of adverse reactions</em></p><p>The following adverse reactions were reported:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Very common (&ge;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Common (&ge;1/100 to &lt;1/10)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>eosinophil count increased</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>headache</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>tachycardia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>flushing, hypotension</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>elevated liver enzyme levels (AST, ALT)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>rash, pruritus</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>fever</p></td><td style="vertical-align:top"><p>chills, catheter site pain</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>decreased potassium, hypomagnesemia, increased glucose, decreased phosphorus, and increased phosphorus</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&bull;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>e-mail: npc.drug@sfda.gov.sa</p><p>Website: <u>https://ade.sfda.gov.sa</u></p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States</p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Inadvertent administration of up to 400 mg of caspofungin in one day has been reported. These occurrences did not result in clinically important adverse reactions. Caspofungin is not dialysable.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antimycotics for systemic use, ATC Code: J02AX04</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Caspofungin acetate is a semi-synthetic lipopeptide (echinocandin) compound synthesised from a fermentation product of&nbsp;<em>Glarea lozoyensis.&nbsp;</em>Caspofungin acetate inhibits the synthesis of beta (1,3)-D-glucan, an essential component of the cell wall of many filamentous fungi and yeast. Beta (1,3)-D-glucan is not present in mammalian cells.</p><p>Fungicidal activity with caspofungin has been demonstrated against&nbsp;<em>Candida</em>&nbsp;yeasts. Studies&nbsp;<em>in vitro</em>&nbsp;and&nbsp;<em>in vivo&nbsp;</em>demonstrate that exposure of&nbsp;<em>Aspergillus</em>&nbsp;to caspofungin results in lysis and death of hyphal apical tips and branch points where cell growth and division occur.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>Caspofungin has&nbsp;<em>in vitro</em>&nbsp;activity against&nbsp;<em>Aspergillus</em>&nbsp;species (<em>Aspergillus fumigatus&nbsp;</em>[N = 75]<em>, Aspergillus flavus&nbsp;</em>[N = 111]<em>, Aspergillus&nbsp;</em>niger [N = 31]<em>, Aspergillus nidulans&nbsp;</em>[N = 8]<em>, Aspergillus terreus&nbsp;</em>[N = 52], and&nbsp;<em>Aspergillus candidus&nbsp;</em>[N = 3]). Caspofungin also has&nbsp;<em>in vitro</em>&nbsp;activity against&nbsp;<em>Candida</em>&nbsp;species (<em>Candida albicans</em>&nbsp;[N = 1,032]<em>, Candida dubliniensis</em>&nbsp;[N = 100]<em>, Candida glabrata</em>&nbsp;[N = 151]<em>, Candida guilliermondii</em>&nbsp;[N = 67]<em>, Candida kefyr</em>&nbsp;[N = 62]<em>, Candida krusei</em>&nbsp;[N = 147]<em>, Candida lipolytica</em>&nbsp;[N = 20]<em>, Candida lusitaniae</em>&nbsp;[N = 80]<em>, Candida parapsilosis</em>&nbsp;[N = 215],&nbsp;<em>Candida rugosa</em>&nbsp;[N = 1], and&nbsp;<em>Candida tropicalis</em>&nbsp;[N = 258]), including isolates with multiple resistance transport mutations and those with acquired or intrinsic resistance to fluconazole, amphotericin B, and 5-flucytosine. Susceptibility testing was performed according to a modification of both the Clinical and Laboratory Standards Institute (CLSI, formerly known as the National Committee for Clinical Laboratory Standards [NCCLS]) method M38-A2 (for&nbsp;<em>Aspergillus</em>&nbsp;species) and method M27-A3 (for&nbsp;<em>Candida</em>&nbsp;species).</p><p>Standardised techniques for susceptibility testing have been established for yeasts by EUCAST. EUCAST breakpoints have not yet been established for caspofungin, due to significant inter-laboratory variation in MIC ranges for caspofungin. In lieu of breakpoints, Candida isolates that are susceptible to anidulafungin as well as micafungin should be considered susceptible to caspofungin.</p><p>Similarly,&nbsp;<em>C.</em>&nbsp;<em>parapsilosis&nbsp;</em>isolates intermediate to anidulafungin and micafungin can be regarded intermediate to caspofungin.</p><p>&nbsp;</p><p><u>Mechanism of resistance</u></p><p>Isolates of Candida with reduced susceptibility to caspofungin have been identified in a small number of patients during treatment (MICs for caspofungin &gt;2 mg/L (4- to 30-fold MIC increases) have been reported using standardised MIC testing techniques approved by the CLSI). The mechanism of resistance identified is FKS1 and/or FKS2 (for&nbsp;<em>C.glabrata</em>) gene mutations. These cases have been associated with poor clinical outcomes.</p><p>Development of&nbsp;<em>in vitro</em>&nbsp;resistance to caspofungin by&nbsp;<em>Aspergillus</em>&nbsp;species has been identified. In limited clinical experience, resistance to caspofungin in patients with invasive aspergillosis has been observed. The mechanism of resistance has not been established. The incidence of resistance to caspofungin by various clinical isolates of&nbsp;<em>Aspergillus</em>&nbsp;is rare. Caspofungin resistance in Candida has been observed but the incidence may differ by species or region.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><em>Invasive Candidiasis in Adult Patients</em>: Two hundred thirty-nine patients were enrolled in an initial study to compare caspofungin and amphotericin B for the treatment of invasive candidiasis. Twenty-four patients had neutropaenia. The most frequent diagnoses were bloodstream infections (candidaemia) (77 %, n=186) and&nbsp;<em>Candida&nbsp;</em>peritonitis (8 %, n=19); patients with&nbsp;<em>Candida</em>&nbsp;endocarditis, osteomyelitis, or meningitis were excluded from this study. Caspofungin 50 mg once daily was administered following a 70 mg loading dose, while amphotericin B was administered at 0.6 to 0.7 mg/kg/day to non-neutropaenic patients or 0.7 to 1.0 mg/kg/day to neutropaenic patients. The mean duration of intravenous therapy was 11.9 days, with a range of 1 to 28 days. A favourable response required both symptom resolution and microbiological clearance of the&nbsp;<em>Candida&nbsp;</em>infection. Two hundred twenty-four patients were included in the primary efficacy analysis (MITT analysis) of response at the end of IV study therapy; favourable response rates for the treatment of invasive candidiasis were comparable for caspofungin (73 % [80/109]) and amphotericin B (62 % [71/115]) [% difference 12.7 (95.6 % CI -0.7, 26.0)]. Among patients with candidaemia, favourable response rates at the end of IV study therapy were comparable for caspofungin (72 % [66/92]) and amphotericin B (63 % [59/94]) in the primary efficacy analysis (MITT analysis) [% difference 10.0 (95.0 % CI -4.5, 24.5)]. Data in patients with non-blood sites of infection were more limited. Favourable response rates in neutropaenic patients were 7/14 (50 %) in the caspofungin group and 4/10 (40 %) in the amphotericin B group. These limited data are supported by the outcome of the empirical therapy study.</p><p>In a second study, patients with invasive candidiasis received daily doses of caspofungin at 50 mg/day (following a 70-mg loading dose on Day 1) or caspofungin at 150 mg/day (see section 4.8). In this study, the caspofungin dose was administered over 2 hours (instead of the routine 1-hour administration). The study excluded patients with suspected&nbsp;<em>Candida</em>&nbsp;endocarditis, meningitis, or osteomyelitis. As this was a primary therapy study, patients who were refractory to prior antifungal agents were also excluded. The number of neutropenic patients enrolled in this study was also limited (8.0 %). Efficacy was a secondary endpoint in this study. Patients who met the entry criteria and received one or more doses of caspofungin study therapy were included in the efficacy analysis. The favourable overall response rates at the end of caspofungin therapy were similar in the 2 treatment groups: 72 % (73/102) and 78 % (74/95) for the caspofungin 50-mg and 150-mg treatment groups, respectively (difference 6.3 % [95 % CI -5.9, 18.4]).</p><p>&nbsp;</p><p><em>Invasive Aspergillosis in Adult Patients</em>: Sixty-nine adult patients (age 18-80) with invasive aspergillosis were enrolled in an open-label, non-comparative study to evaluate the safety, tolerability, and efficacy of caspofungin. Patients had to be either refractory to (disease progression or failure to improve with other antifungal therapies given for at least 7 days) (84 % of the enrolled patients) or intolerant of (16 % of enrolled patients) other standard antifungal therapies. Most patients had underlying conditions (haematologic malignancy [N = 24], allogeneic bone marrow transplant or stem cell transplant [N = 18], organ transplant [N = 8], solid tumour [N = 3], or other conditions [N = 10]). Stringent definitions, modelled after the Mycoses Study Group Criteria, were used for diagnosis of invasive aspergillosis and for response to therapy (favourable response required clinically significant improvement in radiographs as well as in signs and symptoms). The mean duration of therapy was 33.7 days, with a range of 1 to 162 days. An independent expert panel determined that 41 % (26/63) of patients receiving at least one dose of caspofungin had a favourable response. For those patients who received more than 7 days of therapy with caspofungin, 50 % (26/52) had a favourable response. The favourable response rates for patients who were either refractory to or intolerant of previous therapies were 36 % (19/53) and 70 % (7/10), respectively. Although the doses of prior antifungal therapies in 5 patients enrolled as refractory were lower than those often administered for invasive aspergillosis, the favourable response rate during therapy with caspofungin was similar in these patients to that seen in the remaining refractory patients (2/5 versus 17/48, respectively). The response rates among patients with pulmonary disease and extrapulmonary disease were 47 % (21/45) and 28 % (5/18), respectively. Among patients with extrapulmonary disease, 2 of 8 patients who also had definite, probable, or possible CNS involvement had a favourable response.</p><p>&nbsp;</p><p><em>Empirical Therapy in Febrile, Neutropaenic Adult Patients</em>: A total of 1,111 patients with persistent fever and neutropaenia were enrolled in a clinical study and treated with either caspofungin 50 mg once daily following a 70 mg loading dose or liposomal amphotericin B 3.0 mg/kg/day. Eligible patients had received chemotherapy for malignancy or had undergone hematopoietic stem-cell transplantation, and presented with neutropaenia (&lt;500 cells/mm<sup>3</sup>&nbsp;for 96 hours) and fever (&gt;38.0&deg;C) not responding to &ge; 96 hours of parenteral antibacterial therapy. Patients were to be treated until up to 72 hours after resolution of neutropaenia, with a maximum duration of 28 days. However, patients found to have a documented fungal infection could be treated longer. If the drug was well tolerated but the patient&#39;s fever persisted and clinical condition deteriorated after 5 days of therapy, the dosage of study drug could be increased to 70 mg/day of caspofungin (13.3 % of patients treated) or to 5.0 mg/kg/day of liposomal amphotericin B (14.3 % of patients treated). There were 1,095 patients included in the primary Modified Intention-To-Treat (MITT) efficacy analysis of overall favourable response; caspofungin (33.9 %) was as effective as liposomal amphotericin B (33.7 %) [% difference 0.2 (95.2 % CI &ndash;5.6, 6.0)]. An overall favourable response required meeting each of 5 criteria: (1) successful treatment of any baseline fungal infection (caspofungin 51.9 % [14/27], liposomal amphotericin B 25.9 % [7/27]), (2) no breakthrough fungal infections during administration of study drug or within 7 days after completion of treatment (caspofungin 94.8 % [527/556], liposomal amphotericin B 95.5 % [515/539]), (3) survival for 7 days after completion of study therapy (caspofungin 92.6 % [515/556], liposomal amphotericin B 89.2 % [481/539]), (4) no discontinuation from the study drug because of drug-related toxicity or lack of efficacy (caspofungin 89.7 % [499/556], liposomal amphotericin B 85.5 % [461/539]), and (5) resolution of fever during the period of neutropaenia (caspofungin 41.2 % [229/556], liposomal amphotericin B 41.4 % [223/539]). Response rates to caspofungin and liposomal amphotericin B for baseline infections caused by&nbsp;<em>Aspergillus</em>&nbsp;species were, respectively, 41.7 % (5/12) and 8.3 % (1/12), and by&nbsp;<em>Candida</em>&nbsp;species were 66.7 % (8/12) and 41.7 % (5/12). Patients in the caspofungin group experienced breakthrough infections due to the following uncommon yeasts and moulds:&nbsp;<em>Trichosporon</em>&nbsp;species (1),&nbsp;<em>Fusarium</em>&nbsp;species (1),&nbsp;<em>Mucor</em>&nbsp;species (1), and&nbsp;<em>Rhizopus</em>&nbsp;species (1).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The safety and efficacy of caspofungin was evaluated in paediatric patients 3 months to 17 years of age in two prospective, multicentre clinical trials. The study design, diagnostic criteria, and criteria for efficacy assessment were similar to the corresponding studies in adult patients (see section 5.1)<em>.</em></p><p>The first study, which enrolled 82 patients between 2 to 17 years of age, was a randomised, double-blind study comparing caspofungin (50 mg/m<sup>2</sup>&nbsp;IV once daily following a 70-mg/m<sup>2</sup>&nbsp;loading dose on Day 1 [not to exceed 70 mg daily]) to liposomal amphotericin B (3 mg/kg IV daily) in a 2:1 treatment fashion (56 on caspofungin, 26 on liposomal amphotericin B) as empirical therapy in paediatric patients with persistent fever and neutropenia. The overall success rates in the MITT analysis results, adjusted by risk strata, were as follows: 46.6 % (26/56) for caspofungin and 32.2 % (8/25) for liposomal amphotericin B.</p><p>The second study was a prospective, open-label, non-comparative study estimating the safety and efficacy of caspofungin in paediatric patients (ages 6 months to 17 years) with invasive candidiasis, oesophageal candidiasis, and invasive aspergillosis (as salvage therapy). Forty-nine patients were enrolled and received caspofungin at 50 mg/m<sup>2</sup>&nbsp;IV once daily following a 70-mg/m<sup>2</sup>&nbsp;loading dose on Day 1 (not to exceed 70 mg daily), of whom 48 were included in the MITT analysis. Of these, 37 had invasive candidiasis, 10 had invasive aspergillosis, and 1 patient had oesophageal candidiasis. The favourable response rate, by indication, at the end of caspofungin therapy was as follows in the MITT analysis: 81 % (30/37) in invasive candidiasis, 50 % (5/10) in invasive aspergillosis, and 100 % (1/1) in oesophageal candidiasis.</p><p>In a double-blind, randomised (2:1) comparator-controlled study safety, tolerability and efficacy of caspofungin (2 mg/kg/d intravenously, infused over 2 hours) vs amphotericin B deoxycholate (1 mg/kg/d) was evaluated in neonates and infants less than 3 months of age with (culture-confirmed) invasive candidiasis. Due to poor enrolment, the study was terminated early and only 51 patients were randomised. The proportion of patients with fungal-free survival at 2 weeks post-therapy in the caspofungin treatment group (71.0 %) was similar to that seen in the amphotericin B deoxycholate treatment group (68.8 %). Based on this study, no posology recommendations for neonates and infants can be made.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Distribution</u></p><p>Caspofungin is extensively bound to albumin. The unbound fraction of caspofungin in plasma varies from 3.5 % in healthy volunteers to 7.6 % in patients with invasive candidiasis. Distribution plays the prominent role in caspofungin plasma pharmacokinetics and is the rate-controlling step in both the alpha- and beta-disposition phases. The distribution into tissues peaked at 1.5 to 2 days after dosing when 92 % of the dose was distributed into tissues. It is likely that only a small fraction of the caspofungin taken up into tissues later returns to plasma as parent compound. Therefore, elimination occurs in the absence of a distribution equilibrium, and a true estimate of the volume of distribution of caspofungin is currently impossible to obtain.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Caspofungin undergoes spontaneous degradation to an open ring compound. Further metabolism involves peptide hydrolysis and N-acetylation. Two intermediate products, formed during the degradation of caspofungin to this open ring compound, form covalent adducts to plasma proteins resulting in a low-level, irreversible binding to plasma proteins.</p><p><em>In vitro</em>&nbsp;studies show that caspofungin is not an inhibitor of cytochrome P450 enzymes 1A2, 2A6, 2C9, 2C19, 2D6 or 3A4. In clinical studies, caspofungin did not induce or inhibit the CYP3A4 metabolism of other medicinal products. Caspofungin is not a substrate for P-glycoprotein and is a poor substrate for cytochrome P450 enzymes.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The elimination of caspofungin from plasma is slow with a clearance of 10-12 ml/min. Plasma concentrations of caspofungin decline in a polyphasic manner following single 1-hour intravenous infusions. A short alpha-phase occurs immediately post-infusion, followed by a beta-phase with a half-life of 9 to 11 hours. An additional gamma-phase also occurs with a half-life of 45 hours. Distribution, rather than excretion or biotransformation, is the dominant mechanism influencing plasma clearance.</p><p>Approximately 75 % of a radioactive dose was recovered during 27 days: 41 % in urine and 34 % in faeces. There is little excretion or biotransformation of caspofungin during the first 30 hours after administration. Excretion is slow and the terminal half-life of radioactivity was 12 to 15 days. A small amount of caspofungin is excreted unchanged in urine (approximately 1.4 % of dose).</p><p>Caspofungin displays moderate non-linear pharmacokinetics with increased accumulation as the dose is increased, and a dose dependency in the time to reach steady state upon multiple-dose administration.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>Increased caspofungin exposure was seen in adult patients with renal impairment and mild liver impairment, in female subjects, and in the elderly. Generally the increase was modest and not large enough to warrant dosage adjustment. In adult patients with moderate liver impairment or in higher weight patients, a dosage adjustment may be necessary (see below).</p><p>&nbsp;</p><p><em>Weight:</em> Weight was found to influence caspofungin pharmacokinetics in the population pharmacokinetic analysis in adult candidiasis patients. The plasma concentrations decrease with increasing weight. The average exposure in an adult patient weighing 80 kg was predicted to be about 23 % lower than in an adult patient weighing 60 kg (see section 4.2).</p><p>&nbsp;</p><p><em>Hepatic impairment:</em> In adult patients with mild and moderate hepatic impairment, the AUC is increased about 20 and 75 %, respectively. There is no clinical experience in adult patients with severe hepatic impairment and in paediatric patients with any degree of hepatic impairment. In a multiple-dose study, a dose reduction of the daily dose to 35 mg in adult patients with moderate hepatic impairment has been shown to provide an AUC similar to that obtained in adult subjects with normal hepatic function receiving the standard regimen (see section 4.2).</p><p>&nbsp;</p><p><em>Renal impairment</em>: In a clinical study of single 70 mg doses, caspofungin pharmacokinetics were similar in adult volunteers with mild renal impairment (creatinine clearance 50 to 80 ml/min) and control subjects. Moderate (creatinine clearance 31 to 49 ml/min), advanced (creatinine clearance 5 to 30 ml/min), and end-stage (creatinine clearance &lt;10 ml/min and dialysis dependent) renal impairment moderately increased caspofungin plasma concentrations after single-dose administration (range: 30 to 49 % for AUC). However, in adult patients with invasive candidiasis, oesophageal candidiasis, or invasive aspergillosis who received multiple daily doses of caspofungin 50 mg, there was no significant effect of mild to advanced renal impairment on caspofungin concentrations. No dosage adjustment is necessary for patients with renal impairment. Caspofungin is not dialysable, thus supplementary dosing is not required following haemodialysis.</p><p>&nbsp;</p><p><em>Gender:</em> Caspofungin plasma concentrations were on average 17-38 % higher in women than in men.</p><p>&nbsp;</p><p><em>Elderly:</em> A modest increase in AUC (28 %) and C<sub>24h</sub>&nbsp;(32 %) was observed in elderly male subjects compared with young male subjects. In patients who were treated empirically or who had invasive candidiasis, a similar modest effect of age was seen in older patients relative to younger patients.</p><p><em>Race:</em> Patient pharmacokinetic data indicated that no clinically significant differences in the pharmacokinetics of caspofungin were seen among Caucasians, Blacks, Hispanics, and Mestizos.</p><p>&nbsp;</p><p><em>Paediatric Patients:</em> In adolescents (ages 12 to 17 years) receiving caspofungin at 50 mg/m<sup>2</sup>&nbsp;daily (maximum 70 mg daily), the caspofungin plasma AUC<sub>0-24hr</sub>&nbsp;was generally comparable to that seen in adults receiving caspofungin at 50 mg daily. All adolescents received doses &gt;50 mg daily, and, in fact, 6 of 8 received the maximum dose of 70 mg/day. The caspofungin plasma concentrations in these adolescents were reduced relative to adults receiving 70 mg daily, the dose most often administered to adolescents.</p><p>&nbsp;</p><p>In children (ages 2 to 11 years) receiving caspofungin at 50 mg/m<sup>2</sup>&nbsp;daily (maximum 70 mg daily), the caspofungin plasma AUC<sub>0-24hr</sub>&nbsp;after multiple doses was comparable to that seen in adults receiving caspofungin at 50 mg/day.</p><p>In young children and toddlers (ages 12 to 23 months) receiving caspofungin at 50 mg/m<sup>2</sup>&nbsp;daily (maximum 70 mg daily), the caspofungin plasma AUC<sub>0-24hr</sub>&nbsp;after multiple doses was comparable to that seen in adults receiving caspofungin at 50 mg daily and to that in older children (2 to 11 years of age) receiving the 50 mg/m<sup>2</sup>&nbsp;daily dose.</p><p>Overall, the available pharmacokinetic, efficacy, and safety data are limited in patients 3 to 10 months of age. Pharmacokinetic data from one 10-month old child receiving the 50 mg/m<sup>2</sup>&nbsp;daily dose indicated an AUC<sub>0-24hr</sub>&nbsp;within the same range as that observed in older children and adults at the 50 mg/m<sup>2</sup>&nbsp;and the 50 mg dose, respectively, while in one 6-month old child receiving the 50 mg/m<sup>2</sup>&nbsp;dose, the AUC<sub>0-24hr</sub>&nbsp;was somewhat higher.</p><p>In neonates and infants (&lt;3 months) receiving caspofungin at 25 mg/m<sup>2</sup>&nbsp;daily (corresponding mean daily dose of 2.1 mg/kg), caspofungin peak concentration (C<sub>1 hr</sub>) and caspofungin trough concentration (C<sub>24 hr</sub>) after multiple doses were comparable to that seen in adults receiving caspofungin at 50 mg daily. On Day 1, C<sub>1 hr</sub>&nbsp;was comparable and C<sub>24 hr</sub>&nbsp;modestly elevated (36 %) in these neonates and infants relative to adults. However, variability was seen in both C<sub>1 hr</sub>&nbsp;(Day 4 geometric mean 11.73 &micro;g/ml, range 2.63 to 22.05 &micro;g/ml) and C<sub>24 hr</sub>&nbsp;(Day 4 geometric mean 3.55 &micro;g/ml, range 0.13 to 7.17 &micro;g/ml). AUC<sub>0-24hr</sub>&nbsp;measurements were not performed in this study due to the sparse plasma sampling. Of note, the efficacy and safety of caspofungin have not been adequately studied in prospective clinical trials involving neonates and infants under 3 months of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Repeated dose toxicity studies in rats and monkeys using doses up to 7-8 mg/kg given intravenously showed injection site reactions in rats and monkeys, signs of histamine release in rats, and evidence of adverse effects directed at the liver in monkeys. Developmental toxicity studies in rats showed that caspofungin caused decreases in foetal body weights and an increase in the incidence of incomplete ossification of vertebra, sternebra, and skull bone at doses of 5 mg/kg that were coupled to adverse maternal effects such as signs of histamine release in pregnant rats. An increase in the incidence of cervical ribs was also noted. Caspofungin was negative in&nbsp;<em>in vitro</em>&nbsp;assays for potential genotoxicity as well as in the&nbsp;<em>in vivo</em>&nbsp;mouse bone marrow chromosomal test. No long-term studies in animals have been performed to evaluate the carcinogenic potential. For caspofungin, there were no effects on fertility in studies conducted in male and female rats up to 5 mg/kg/day.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp; Sucrose</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Mannitol</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Glacial acetic acid</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Sodium hydroxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Do not mix with diluents containing glucose, as caspofungin is not stable in diluents containing glucose. In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.

Reconstituted concentrate: should be used immediately. Stability data have shown that the concentrate for solution for infusion can be stored for up to 24 hours when the vial is stored at 25°C or less and reconstituted with water for injection.

Diluted patient infusion solution: should be used immediately. Stability data have shown that the product can be used within 24 hours when stored at 25°C or less, or within 48 hours when the intravenous infusion bag (bottle) is stored refrigerated (2 to 8°C) and diluted with sodium chloride solution 9 mg/ml (0.9 %), 4.5 mg/ml (0.45 %), or 2.25 mg/ml (0.225 %) for infusion or lactated ringer's solution.

Kanvasiv contains no preservatives. From a microbiological point of view, the product should be used immediately. If not used immediately, in use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless reconstitution and dilution have taken place in controlled validated aseptic conditions.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Unopened vials: Store in a refrigerator (2-8&deg;C).</p><p>Store in the original package in order to protect from light.</p><p>For storage conditions after reconstitution and dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">10 ml clear type I glass vials sealed with bromo-butyl rubber stoppers and aluminum band with plastic flip-off caps.</p><p style="text-align:justify">Pack size: 1 Vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Reconstitution of Kanvasiv</strong></p><p>Do not use any diluents containing glucose, as caspofungin is not stable in diluents containing glucose. Do not mix or co-infuse caspofungin with any other medicines, as there are no data available on the compatibility of caspofungin with other intravenous substances, additives, or medicinal products. Visually inspect the infusion solution for particulate matter or discolouration.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p><strong>Kanvasiv 50 mg Powder for Concentrate for Solution for Infusion</strong></p><p><u>Instructions for use in adult patients</u></p><p><em>Step 1 Reconstitution of conventional vials</em></p><p>To reconstitute the powder, bring the vial to room temperature and aseptically add 10.5 ml of water for injection. The concentrations of the reconstituted vials will be: 5.2 mg/ml.</p><p>The white to off-white compact lyophilised powder will dissolve completely. Mix gently until a clear solution is obtained. Reconstituted solutions should be visually inspected for particulate matter or discolouration. This reconstituted solution may be stored for up to 24 hours at or below 25&deg;C.</p><p>&nbsp;</p><p><em>Step 2 Addition of reconstituted Kanvasiv to patient infusion solution</em></p><p>Diluents for the final solution for infusion are: sodium chloride solution for injection or lactated ringer&#39;s solution. The solution for infusion is prepared by aseptically adding the appropriate amount of reconstituted concentrate (as shown in the table below) to a 250 ml infusion bag or bottle. Reduced volume infusions in 100 ml may be used, when medically necessary, for 50 mg or 35 mg daily doses. Do not use if the solution is cloudy or has precipitated.</p><p>&nbsp;</p><p><strong>Preparation of the solution for infusion in adults</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Dose*</strong></p></td><td style="vertical-align:top"><p><strong>Volume of recon- stituted Kanvasiv for transfer to intravenous bag or bottle</strong></p></td><td style="vertical-align:top"><p><strong>Standard preparation</strong></p><p>(reconstituted Kanvasiv added to 250 ml) final concentration</p></td><td style="vertical-align:top"><p><strong>Reduced volume infusion</strong></p><p>(reconstituted Kanvasiv added to 100 ml) final concentration</p></td></tr><tr><td><p>50 mg</p></td><td><p>10 ml</p></td><td><p>0.20 mg/ml</p></td><td><p>-</p></td></tr><tr><td><p>50 mg at reduced volume</p></td><td><p>10 ml</p></td><td><p>-</p></td><td><p>0.47 mg/ml</p></td></tr><tr><td><p>35 mg for moderate hepatic impairment</p><p>(from one 50 mg vial)</p></td><td><p>7 ml</p></td><td><p>0.14 mg/ml</p></td><td><p>-</p></td></tr><tr><td><p>35 mg for moderate hepatic impairment</p><p>(from one 50 mg vial) at reduced volume</p></td><td><p>7 ml</p></td><td><p>-</p></td><td><p>0.34 mg/ml</p></td></tr></tbody></table><p>*10.5 ml should be used for reconstitution of all vials.</p><p><u>Instructions for use in paediatric patients</u></p><p><em>Calculation of Body Surface Area (BSA) for paediatric dosing</em></p><p>Before preparation of infusion, calculate the body surface area (BSA) of the patient using the following formula: (Mosteller Formula)</p><p><img src="data:image/png;base64,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" alt="" width="279" height="59" vspace="0" hspace="0" border="0" style="width:279px;height:59px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><em>Preparation of the 70 mg/m<sup>2&nbsp;</sup>infusion for paediatric patients &gt;3 months of age (using a 50-mg vial)</em></p><p>1. Determine the actual loading dose to be used in the paediatric patient by using the patient&#39;s BSA (as calculated above) and the following equation:</p><p>&nbsp;&nbsp;&nbsp; BSA (m<sup>2</sup>) X 70 mg/m<sup>2</sup>&nbsp;= Loading Dose</p><p>&nbsp;&nbsp;&nbsp; The maximum loading dose on Day 1 should not exceed 70 mg regardless of the patient&#39;s calculated dose.</p><p>2. Equilibrate the refrigerated vial of Kanvasiv to room temperature.</p><p>3. Aseptically add 10.5 ml of water for injection.&nbsp;<sup>a</sup>&nbsp;This reconstituted solution may be stored for up to 24 hours at or below 25&deg;C.<sup>b</sup>&nbsp;This will give a final caspofungin concentration in the vial of 5.2 mg/ml.</p><p>4. Remove the volume of medicinal product equal to the calculated loading dose (Step 1) from the vial. Aseptically transfer this volume (ml)<sup>c</sup>&nbsp;of reconstituted Kanvasiv to an IV bag (or bottle) containing 250 ml of 0.9%, 0.45%, or 0.225% sodium chloride injection or lactated ringer&rsquo;s injection. Alternatively, the volume (ml)<sup>c</sup>&nbsp;of reconstituted Kanvasiv can be added to a reduced volume of 0.9%, 0.45%, or 0.225% sodium chloride injection or lactated ringer&rsquo;s injection, not to exceed a final concentration of 0.5 mg/ml. This infusion solution must be used within 24 hours if stored at or below 25&deg;C or within 48 hours if stored refrigerated at 2 to 8&deg;C.</p><p>&nbsp;</p><p><em>Preparation of the 50 mg/m<sup>2&nbsp;</sup>infusion for paediatric patients &gt;3 months of age (using a 50-mg vial)</em></p><p>1. Determine the actual daily maintenance dose to be used in the paediatric patient by using the patient&#39;s BSA (as calculated above) and the following equation:</p><p>&nbsp;&nbsp;&nbsp; BSA (m<sup>2</sup>) X 50 mg/m<sup>2</sup>&nbsp;= Daily Maintenance Dose</p><p>&nbsp;&nbsp;&nbsp; The daily maintenance dose should not exceed 70 mg regardless of the patient&#39;s calculated dose.</p><p>2. Equilibrate the refrigerated vial of Kanvasiv to room temperature.</p><p>3. Aseptically add 10.5 ml of water for injection.<sup>a</sup>&nbsp;This reconstituted solution may be stored for up to 24 hours at or below 25&deg;C.<sup>b</sup>&nbsp;This will give a final caspofungin concentration in the vial of 5.2 mg/ml.</p><p>4. Remove the volume of medicinal product equal to the calculated daily maintenance dose (Step 1) from the vial. Aseptically transfer this volume (ml)<sup>c</sup>&nbsp;of reconstituted Kanvasiv to an IV bag (or bottle) containing 250 ml of 0.9%, 0.45%, or 0.225% sodium chloride injection or lactated ringer&rsquo;s injection. Alternatively, the volume (ml)<sup>c</sup>&nbsp;of reconstituted Kanvasiv can be added to a reduced volume of 0.9%, 0.45%, or 0.225% sodium chloride injection or lactated ringer&rsquo;s injection, not to exceed a final concentration of 0.5 mg/ml. This infusion solution must be used within 24 hours if stored at or below 25&deg;C or within 48 hours if stored refrigerated at 2 to 8&deg;C.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Preparation notes:</strong></p><p><strong>a.&nbsp;</strong>The white to off-white cake will dissolve completely. Mix gently until a clear solution is obtained.</p><p><strong>b.</strong>&nbsp;Visually inspect the reconstituted solution for particulate matter or discolouration during reconstitution and prior to infusion. Do not use if the solution is cloudy or has precipitated.</p><p><strong>c.</strong>&nbsp;Kanvasiv is formulated to provide the full labelled vial dose (50 mg) when 10 ml is withdrawn from the vial.</p></td></tr></tbody></table><p><strong><u>&nbsp;</u></strong></p><p><strong>Kanvasiv 70 mg Powder for Concentrate for Solution for Infusion</strong></p><p><u>Instructions for use in adult patients</u></p><p><em>Step 1 Reconstitution of conventional vials</em></p><p>To reconstitute the powder bring the vial to room temperature and aseptically add 10.5 ml of water for injection. The concentrations of the reconstituted vials will be: 7.2 mg/ml.</p><p>The white to off-white compact lyophilised powder will dissolve completely. Mix gently until a clear solution is obtained. Reconstituted solutions should be visually inspected for particulate matter or discolouration. This reconstituted solution may be stored for up to 24 hours at or below 25&deg;C.</p><p>&nbsp;</p><p><em>Step 2 Addition of reconstituted Kanvasiv to patient infusion solution</em></p><p>Diluents for the final solution for infusion are: sodium chloride solution for injection or lactated ringer&#39;s solution. The solution for infusion is prepared by aseptically adding the appropriate amount of reconstituted concentrate (as shown in the table below) to a 250 ml infusion bag or bottle. Reduced volume infusions in 100 ml may be used, when medically necessary, for 50 mg or 35 mg daily doses. Do not use if the solution is cloudy or has precipitated.</p><p>&nbsp;</p><p><strong>Preparation of the solution for infusion in adults</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Dose*</strong></p></td><td style="vertical-align:top"><p><strong>Volume of recon- stituted Kanvasiv for transfer to intravenous bag or bottle</strong></p></td><td style="vertical-align:top"><p><strong>Standard preparation</strong></p><p>(reconstituted Kanvasiv added to 250 ml) final concentration</p></td><td style="vertical-align:top"><p><strong>Reduced volume infusion</strong></p><p>(reconstituted Kanvasiv added to 100 ml) final concentration</p></td></tr><tr><td><p>70 mg</p></td><td><p>10 ml</p></td><td><p>0.28 mg/ml</p></td><td><p>Not Recommended</p></td></tr><tr><td><p>70 mg</p><p>(from two 50 mg vials)**</p></td><td><p>14 ml</p></td><td><p>0.28 mg/ml</p></td><td><p>Not Recommended</p></td></tr><tr><td><p>35 mg for moderate hepatic impairment</p><p>(from one 70 mg vial)</p></td><td><p>5 ml</p></td><td><p>0.14 mg/ml</p></td><td><p>0.34 mg/ml</p></td></tr></tbody></table><p>* 10.5 ml should be used for reconstitution of all vials.</p><p>**If 70 mg vial is not available, the 70 mg dose can be prepared from two 50 mg vials.</p><p>&nbsp;</p><p><u>Instructions for use in paediatric patients</u></p><p><em>Calculation of Body Surface Area (BSA) for paediatric dosing</em></p><p>Before preparation of infusion, calculate the body surface area (BSA) of the patient using the following formula: (Mosteller Formula)</p><p><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAARMAAAA/CAMAAAGDaezlAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAADPUExURQAAAPr6+jY2NgICAgEBAQMDAwYGBgUFBQQEBBMTEwoKCgcHBw4ODgkJCQ0NDQ8PDwgICBUVFVRUVO3t7ezs7Pv7++jo6Pn5+fj4+N7e3vb29vPz8/z8/PHx8ff39/Dw8PT09O7u7vX19ebm5u/v7/Ly8uvr6xQUFOnp6eTk5Orq6uDg4N3d3d/f3xAQEBgYGOHh4RkZGQwMDAsLC+fn5+Xl5RoaGhcXF+Pj4x4eHhYWFhEREdvb20xMTD4+PtnZ2djY2BISEiMjI9zc3AAAANe9KXQAAABFdFJOU///////////////////////////////////////////////////////////////////////////////////////////ALLusTgAAAAJcEhZcwAADsMAAA7DAcdvqGQAAAkFSURBVGhD7ZtJkhu5EkRpfYRec8O9bkCzXnyr+5+p/T2PHFhkSaRq6DJ9eiWBQCAQE5BIMCkdXn6Nx2WOx5fjkAtOx+OFzPHloMhB7iG954yKnlNkZ/ThJqIngyEurV5YfNzn27hD5mGR4wlXifZ4IlaIC5EwEhwpaaTJyCFjDgyMdDL08vIPGbjE+aCWlORoy8cx2R0yqKHRcht7X97AHSJ34LO1kNld6KaEdIbJlcbxlBybjDe0yD4GQ5jpanJYkhuZ5J4ZQyGKT04f0xbCcechHGifnmSiNn67uJgwNXi5OCo2whtqHuFh7KDHhQYtHsZOyzvw1HIbb2rxVmfGWgZdDewdw0ak8/6mFpYj0qwyPkhTZQtlu63qlGfYN7Vki0IiS52F75jNZlZwhqWIL5QL/wonuBmYSjU6M4CCP76sDAdQldCPGGH8XfhLK7ljVdM8QJ2y5Xbzq8O1wZZ5OOz4DCWu9f6KwI8yCSNoeQF0pKyaS2Sr0VbNVWPJa+j0LkUbXtl8U8PPsdeCit9TcyP+38B30vIheLpyC4+7cv+dfhfyhA44cD3uCtscd8l6y7ZiNxiinGkGEIv8+kkRjqfbGfqAK5HnOrB9pel2mXg461ULxwkPfm0iREWdYuTZzdKf/YXaLYYnSnC/K5FfNzg3w4SkPvdFDrRy+4dMOvQiHnpGrXz2Vh8LDNTNyQmcKJgAZLVRHgx2Zbi0iCnktuWqb9CJ6yCkVhM7LPLs9aPXQASucIzL+ZvnXNqkK91h+zQ0YCRxgCnY7/1bGGotiXwo2n0kbCNWeTwBdqWGi0+EG7NYPuShTQL7l565Fsyq+ClGs/FqIcWm4W1UNZJJHV/c8IgpbS5Ru0sDvg75EyiSk0izevMRegu3o9y4u4x8Nm66spuT5vpLcDsr/wmertzC93Hl6ck1np5c4+nJNR735C9PoRt6Kn0f/o7exz3Jc7aPo6lTcC2PqJWeB1ikhnVBLGQk5lzzsCeo4VDVQ13ACZJ6aQ9GrMZwh/58Rlg6mONYGr+zTjJmOwVhQSXrYSRHHMrpT+mhsG2+WPwgjJfz8YcCPepHzd2eKC7BK5mcpjhQObqHPI6hEYDbaD3SU3EO3uSpfeEAOLkuJ7C7PQk8fp49pGP0R8dyHE6FmfG0tZRVRjmfCuQbilwmFQdfzvkCAx7whKlmMK9VOR7qjoZzTFTpMge5BqUyDDLjTNpowimGjfQDnpBY5hc3oqB6ooZpYf5ZH0vWkcY7UMeZIhg1Hj/MFLOjUD2px16osJgazQyj0hNyuwhI7ekh9I8eu6UHI89HPU1Qb0MoeDFpnXIik8QLKtqJO8H84EvSzzA73UMbHkvF3ISeYqziE536OTkB/E6ivxtWWq8XrKHtBAqbihLv0Xd+cJtJptE2s2kb2gH5PltaFelWTwqh0NDsEyC8BqY0wXSHA6s8mwie6E3cSFVPZmhoreCY68zZLE/g6ZBvQmvIhcAPNNwDTGm1rUAXOwum7PC/1Tyqf6kWAfKBL6PtLleak3oEuQ5EhWmBuarC6V9AAb75Ix31o++XIBfHLF0mbhmTjSJ6uJzjvaI7lLoaZ1pIzCsNb6Kz8hpZp47+dQY+Drc9IZ6F+Crc9mT1Y79HfDLe8qQOcLt/Fd7w5D/A05NrPD25xvfx5PvgmZNrPHNyjWdOrvHMyTWeObnGMyfX+Pyc+PVtvlxTLaf17agekms6tvbA1jYgldTUVHSl4LuVXPkh26FITbdFPf3TzccevvZ9xTrh59/FKP+oSfAbdimR1tpEqv4u4I3FvonC1tNWpG9KZhzZga7idNiHoKrhjehSaVRdX5ATTfjbcb7fG1u88D0Nnswy0s9h9Wv9SKbM0MhAeaElzLJoUoxEf6KGqPQLb0jNcJMUXhjx6Ni3PSl5XZkOiqr/mpyMj4ZmbnBXBmhMCU3gUj1sOyCUNcYg6bhwnBATaDI1UupzXKpmmC5qBzJ2kax/yndEuz8adcgiUzSvpgtD901V32SRJF6rcSFPMyNx024GKoznO+0IQMqM1Ok8io3dIcjwTmuMhpHpSBMxK1J7YGGhnsW0IH0fDtcptWWsZnXytos4j76o5V+JGpcRGMXpHL/qNK+fEUeC91sTp/GLNIhjaUdDdRHMpP6MIsJLpQIDzaBwkGFs1dcRehd8Sk4IDsWYMmRDwpnxiQrKd5P9cOHZxDASp8mJqVJF4lh0DJSNBAsSvn2LfvVhvQ6ohw/NiEag1lCstoC+D0csOVl6EQv4whX7GK59L83T45UiVZOzXq3V1vbc/YwqZJIrSS1NP7qgZFeKhHGf2KF3qLZ3gR53fFpkOzTaZfvotCNdPhymtXFTeytuesMKeTicl/VfYTs2pBERDc6IBWZxMcYfq06JEDxBib5+IWZ9qQFc6x+RU29mRLyHTNvWzzgYm84UIx8OdqstWiBOPtDSm/WGqgqlUHABHfmLQf5LBQbaGek9Kue1h8JWxRCq5M98SA5nFR/JBelbrmGsQg50mFRlQ5s+cyLbFROkLMubzB9XlOYm5odeRzOU/HKvO1pDdrQTpr+NKWZvBS5QudsYhSBZYPT8xaJbeDn6k1Bsv8alfmk4hG5LTjRUzlaK/dZlTry/tiE93sD3LmebSD/pmicsY5YfBhGjjbSUzMi52DG8x1iQWgoQgstEDEMWXsUo6kKbab3DXxpcezCMv1Gjjo1oHlx1FVq7UxFz3c2zMK6YEPfjyJqHppVk5YM/+pQnauQRCF/V6NiBnnPEND683wMW3EZiz2cLBAaTE3SPifcZ2cNMq9EskJPeEWmaHwjM0TAN4SHqinW0Urla75Cx/c+B74MBd6/MZGj/eGYdpcVPtzhxZfs9wATW+N9fPU0RSbAmgwzEgy0n9HAfMlN4yx2ZS58uHItet+J3osq9vFta4U6IGIeFOx8GFRJPSuy0qhP90EtF/PTbLad7ynZT5tphWpfM34OudKL2VXRPi7+PMFQw5XeiCZoGsCn3z8JDOfEmWpBv3fD+uIw8kpPkwz1kmubjI+/i74MH1sncN2tWWDf7HP0xeCQn/y945uQaz5xc45mT13h5+RejA6Wh7vO6oAAAAABJRU5ErkJggg==" alt="" width="275" height="63" vspace="0" hspace="0" border="0" style="width:275px;height:63px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><em>Preparation of the 70 mg/m<sup>2&nbsp;</sup>infusion for paediatric patients &gt;3 months of age (using a 70-mg vial)</em></p><p>1. Determine the actual loading dose to be used in the paediatric patient by using the patient&#39;s BSA (as calculated above) and the following equation:</p><p>&nbsp;&nbsp;&nbsp; BSA (m<sup>2</sup>) X 70 mg/m<sup>2</sup>&nbsp;= Loading Dose</p><p>&nbsp;&nbsp;&nbsp; The maximum loading dose on Day 1 should not exceed 70 mg regardless of the patient&#39;s calculated dose.</p><p>2. Equilibrate the refrigerated vial of Kanvasiv to room temperature.</p><p>3. Aseptically add 10.5 ml of water for injection.<sup>a</sup>&nbsp;This reconstituted solution may be stored for up to 24 hours at or below 25&deg;C.<sup>b</sup>&nbsp;This will give a final caspofungin concentration in the vial of 7.2 mg/ml.</p><p>4. Remove the volume of medicinal product equal to the calculated loading dose (Step 1) from the vial. Aseptically transfer this volume (ml)<sup>c</sup>&nbsp;of reconstituted Kanvasiv to an IV bag (or bottle) containing 250 ml of 0.9 %, 0.45 %, or 0.225 % sodium chloride injection or lactated ringer&rsquo;s injection. Alternatively, the volume (ml)<sup>c</sup>&nbsp;of reconstituted Kanvasiv can be added to a reduced volume of 0.9 %, 0.45 %, or 0.225 % sodium chloride injection or lactated ringer&rsquo;s injection, not to exceed a final concentration of 0.5 mg/ml. This infusion solution must be used within 24 hours if stored at or below 25&deg;C or within 48 hours if stored refrigerated at 2 to 8&deg;C.</p><p>&nbsp;</p><p><em>Preparation of the 50 mg/m<sup>2&nbsp;</sup>infusion for paediatric patients &gt;3 months of age (using a 70-mg vial)</em></p><p>1. Determine the actual daily maintenance dose to be used in the paediatric patient by using the patient&#39;s BSA (as calculated above) and the following equation:</p><p>&nbsp;&nbsp;&nbsp; BSA (m<sup>2</sup>) X 50 mg/m<sup>2</sup>&nbsp;= Daily Maintenance Dose</p><p>&nbsp;&nbsp;&nbsp; The daily maintenance dose should not exceed 70 mg regardless of the patient&#39;s calculated dose.</p><p>2. Equilibrate the refrigerated vial of Kanvasiv to room temperature.</p><p>3. Aseptically add 10.5 ml of water for injection.<sup>a</sup>&nbsp;This reconstituted solution may be stored for up to 24 hours at or below 25&deg;C.<sup>b</sup>&nbsp;This will give a final caspofungin concentration in the vial of 7.2 mg/ml.</p><p>4. Remove the volume of medicinal product equal to the calculated daily maintenance dose (Step 1) from the vial. Aseptically transfer this volume (ml)<sup>c</sup>&nbsp;of reconstituted Kanvasiv to an IV bag (or bottle) containing 250 ml of 0.9 %, 0.45 %, or 0.225 % sodium chloride injection or lactated ringer&rsquo;s injection. Alternatively, the volume (ml)<sup>c</sup>&nbsp;of reconstituted Kanvasiv can be added to a reduced volume of 0.9 %, 0.45 %, or 0.225 % sodium chloride injection or lactated ringer&rsquo;s injection, not to exceed a final concentration of 0.5 mg/ml. This infusion solution must be used within 24 hours if stored at or below 25&deg;C or within 48 hours if stored refrigerated at 2 to 8&deg;C.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Preparation notes:</strong></p><p><strong>a.&nbsp;</strong>The white to off-white cake will dissolve completely. Mix gently until a clear solution is obtained.</p><p><strong>b.</strong>&nbsp;Visually inspect the reconstituted solution for particulate matter or discolouration during reconstitution and prior to infusion. Do not use if the solution is cloudy or has precipitated.</p><p><strong>c.</strong>&nbsp;Kanvasiv is formulated to provide the full labelled vial dose (70 mg) when 10 ml is withdrawn from the vial.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. BOX 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                23 June 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>